nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-998Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESПрименение ритуксимаба при идиопатическом гломерулонефрите и системных заболеваниях с поражением почек (обзор литературы)Rituximab in treatment of idiopathic glomerulonephritis and systemic diseases affecting kidneys (review)ЗахароваЕ. В.ZakharovaE. V.helena.zakharova@gmail.comГУЗ г. Москвы Городская клиническая больница имени С.П. Боткина, Кафедра нефрологии МГМСУРоссияS.P. Botkin Moscow clinical city hospital, Chair of Nephrology MSMSURussian Federation201017062025123174178Copyright © Захарова Е.В., 20252025Захарова Е.В.Zakharova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/998

В данном обзоре мы представляем данные международной литературы, касающиеся обоснования, дозирования и результатов применения анти-CD20 моноклональных антител (Ритуксимаба) при хроническом гломерулонефрите с нефротическим синдромом, системной красной волчанке, АНЦА-ассоциированных васкулитах и HCV-ассоциированном криоглобулинемическом васкулите.

We present here a review of data concerning rationale, dosage and efficacy of anti-CD20 monoclonal antibodies (Rituximab) in chronic glomerulonephritis with nephrotic syndrome, systemic lupus erythematosus, ANCA-associated vasculitis and HCV-associated cryoglobulinemia.

ритуксимабиммуносупрессивная терапиягломерулонефритсистемная красная волчанкасистемные васкулитыrituximabimmunosuppressive therapyglomerulonephritissystemic lupus erythematosussystemic vasculitisReferencesAhmed M.S., Wong C.F. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? // J Nephrol, 2007. Vol. 20. P. 350-356Ahmed M.S., Wong C.F. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? // J Nephrol, 2007. Vol. 20. P. 350-356Ahmed M.S., Wong C.F. Rituximab and nephritic syndrome: a new therapeutic hope? // NDT, 2008. Vol. 23. P. 11-17Ahmed M.S., Wong C.F. Rituximab and nephritic syndrome: a new therapeutic hope? // NDT, 2008. Vol. 23. P. 11-17Bagga A., Sinha A., Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome // N Engl J Med, 2007. Vol. 356. P. 2751-2752Bagga A., Sinha A., Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome // N Engl J Med, 2007. Vol. 356. P. 2751-2752Benz K., Dotsch J., Rascher W. et al. Change of course of steroid-dependent nephrotic syndrome after rituximab therapy // Pediatr Nephrol, 2004. Vol. 19. P. 794-797Benz K., Dotsch J., Rascher W. et al. Change of course of steroid-dependent nephrotic syndrome after rituximab therapy // Pediatr Nephrol, 2004. Vol. 19. P. 794-797Bosch X. Rituximab in ANCA vasculitis: bittersweet results // Nature reviews, 2010. Vol. 6. P. 137-139Bosch X. Rituximab in ANCA vasculitis: bittersweet results // Nature reviews, 2010. Vol. 6. P. 137-139Cacoub P., Delluc A., Saadon D. et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? // Ann Rheum Dis, 2008. Vol. 67. P. 283-287Cacoub P., Delluc A., Saadon D. et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? // Ann Rheum Dis, 2008. Vol. 67. P. 283-287E.D. Charles, L.D. Dustin. Hepatitis C virus-induced cryoglobulinemia // Kidney Int, 2009. Vol. 76. P. 818-824E.D. Charles, L.D. Dustin. Hepatitis C virus-induced cryoglobulinemia // Kidney Int, 2009. Vol. 76. P. 818-824Cobo M., Hernandez D., Rodriguez C. et al. Successful therapeutic use of rituximab in refractory membranous glomerulonephritis // Clin Nephrol, 2006. Vol. 66. P. 54-57Cobo M., Hernandez D., Rodriguez C. et al. Successful therapeutic use of rituximab in refractory membranous glomerulonephritis // Clin Nephrol, 2006. Vol. 66. P. 54-57Favas C., Isenberg D.A. B-cell depletion therapy in SLE – what are current prospects for its acceptance? // Nat Rev Rheumatol, 2009. Vol. 5. P. 711-2009Favas C., Isenberg D.A. B-cell depletion therapy in SLE – what are current prospects for its acceptance? // Nat Rev Rheumatol, 2009. Vol. 5. P. 711-2009Ferrario A.J., Smith S.W., Neil D. et al. Relapsed Wegener’s granulomatosis after rituximab therapy-B cells are present in new pathological lesions despite persistent “depletion” of peripheral blood // NDT, 2008. Vol. 23. P. 3030-3032Ferrario A.J., Smith S.W., Neil D. et al. Relapsed Wegener’s granulomatosis after rituximab therapy-B cells are present in new pathological lesions despite persistent “depletion” of peripheral blood // NDT, 2008. Vol. 23. P. 3030-3032Fervenza F.C., Cosio F.G., Erickson S.B. et al. Rituximab treatment in idiopathic membranous nephropathy // Kidney Int, 2008. Vol. 73. P. 117-125Fervenza F.C., Cosio F.G., Erickson S.B. et al. Rituximab treatment in idiopathic membranous nephropathy // Kidney Int, 2008. Vol. 73. P. 117-125Francois H., Daugas E., Bensman A. et al. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in adult; first case report and pathophysiological considerations // Am J kidney Dis, 2007. Vol. 49. P. 158-161Francois H., Daugas E., Bensman A. et al. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in adult; first case report and pathophysiological considerations // Am J kidney Dis, 2007. Vol. 49. P. 158-161Furie R. et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results of randomized, double-blind phase III LUNAR study // Arthritis Rheum, 2009 [online]Furie R. et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results of randomized, double-blind phase III LUNAR study // Arthritis Rheum, 2009 [online]Furie R. et al. Effect of rituximab (RTX) on anti-dsDNA and C3 levels and relationship to response: results from the LUNAR trial // Arthritis Rheum, 2009 [online]Furie R. et al. Effect of rituximab (RTX) on anti-dsDNA and C3 levels and relationship to response: results from the LUNAR trial // Arthritis Rheum, 2009 [online]Gilbert R.D., Hulse E., Rigden S. Rituximab therapy for steroid-dependent minimal change nephritic syndrome // Pediatr Nephrol, 2006. Vol. 21. P. 1698-1700Gilbert R.D., Hulse E., Rigden S. Rituximab therapy for steroid-dependent minimal change nephritic syndrome // Pediatr Nephrol, 2006. Vol. 21. P. 1698-1700Hofstra J.M., Deegens J.K., Wetzels J.F. Rituximab: effective treatment for severe steroid-dependent minimal-change nephrotic syndrome? // NDT, 2007. Vol. 22. P. 2100-2102Hofstra J.M., Deegens J.K., Wetzels J.F. Rituximab: effective treatment for severe steroid-dependent minimal-change nephrotic syndrome? // NDT, 2007. Vol. 22. P. 2100-2102Lovric S., Erdbruegger U., Kumpers P. et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-center experience with 15 patients // NDT, 2009. Vol. 24. P. 179-185Lovric S., Erdbruegger U., Kumpers P. et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-center experience with 15 patients // NDT, 2009. Vol. 24. P. 179-185Merrill J.T. et al. Flare assessment in systemic lupus erythematosus (SLE) patients treated with rituximab in phase II/III EXPLORER trial // Arthritis Rheum, 2009 [online]Merrill J.T. et al. Flare assessment in systemic lupus erythematosus (SLE) patients treated with rituximab in phase II/III EXPLORER trial // Arthritis Rheum, 2009 [online]Merrill J.T. et al. Treatment of systemic lupus erythematosus (SLE) with rituximab: 78 week safety data from phase II/III EXPLORER trial // Arthritis Rheum, 2009 [online]Merrill J.T. et al. Treatment of systemic lupus erythematosus (SLE) with rituximab: 78 week safety data from phase II/III EXPLORER trial // Arthritis Rheum, 2009 [online]Nellessen C.M., Poge U., Brensing K.A. et al. Diffuse alveolar hemorrhage in systemic lupus erythematosus patient successfully treated with rituximab: a case report // NDT, 2008. Vol. 23. P. 385-386Nellessen C.M., Poge U., Brensing K.A. et al. Diffuse alveolar hemorrhage in systemic lupus erythematosus patient successfully treated with rituximab: a case report // NDT, 2008. Vol. 23. P. 385-386Remuzzi G., Chiurchiu C., Abbate V. et al. Rituximab for idiopathic membranous nephropathy // Lancet, 2002. Vol. 360. P. 923-924Remuzzi G., Chiurchiu C., Abbate V. et al. Rituximab for idiopathic membranous nephropathy // Lancet, 2002. Vol. 360. P. 923-924Rossi P., Demoux A.L., Granel B. et al. Anti-CD20 monoclonal antibody or treatment of refractory autoimmune haemolytic anemia associated with idiopathic membranous nephropathy // Rheumatology (Oxford), 2005. Vol. 44. P. 403-405Rossi P., Demoux A.L., Granel B. et al. Anti-CD20 monoclonal antibody or treatment of refractory autoimmune haemolytic anemia associated with idiopathic membranous nephropathy // Rheumatology (Oxford), 2005. Vol. 44. P. 403-405Ruggenenti P., Chiurchiu C., Brusegan V. et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study // Am J Soc Nephrol, 2003. Vol. 14. P. 1851-1857Ruggenenti P., Chiurchiu C., Brusegan V. et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study // Am J Soc Nephrol, 2003. Vol. 14. P. 1851-1857Saadoun D., Rosenzwaig M., Landau D. et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis // Blood, 2008. Vol. 111. P. 5334-5341Saadoun D., Rosenzwaig M., Landau D. et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis // Blood, 2008. Vol. 111. P. 5334-5341Saadoun D., Rigon M.R., Sene D. et al. Rituximab Plus Peg-Interferon-alpha/Ribaverin Compared with Peg-Interferon-alpha/Ribaverin in Hepatitis C-Related Mixed Cryoglobulinemia // Blood, 2010. Vol. 116. P 326-354Saadoun D., Rigon M.R., Sene D. et al. Rituximab Plus Peg-Interferon-alpha/Ribaverin Compared with Peg-Interferon-alpha/Ribaverin in Hepatitis C-Related Mixed Cryoglobulinemia // Blood, 2010. Vol. 116. P 326-354Sansonno D., De RE V., Lauetta G. et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with anti-CD20 // Blood, 2003. Vol. 101. P. 3818-3826Sansonno D., De RE V., Lauetta G. et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with anti-CD20 // Blood, 2003. Vol. 101. P. 3818-3826Sanz I., Lee F.E. B Cells as Therapeutic Targets in SLE // Nat Rev Rheumatol, 2010. Vol. 6. P. 326-337Sanz I., Lee F.E. B Cells as Therapeutic Targets in SLE // Nat Rev Rheumatol, 2010. Vol. 6. P. 326-337Sfikakis P.P., Boletis J.N., Lionaki S. et al. Remission of proliferative lupus nephritis following B-cell depletion therapy is preceded by down-regulation of the T cell co-stimulatory molecule CD40 ligand: an open-label trial // Arthritis Rheum, 2005. Vol. 52. P. 501-513Sfikakis P.P., Boletis J.N., Lionaki S. et al. Remission of proliferative lupus nephritis following B-cell depletion therapy is preceded by down-regulation of the T cell co-stimulatory molecule CD40 ligand: an open-label trial // Arthritis Rheum, 2005. Vol. 52. P. 501-513Smith G.C. Is there a role of rituximab in the treatment of idiopathic childhood nephrotic syndrome? // Pediatr nephrol, 2007. Vol. 22. P. 893-898Smith G.C. Is there a role of rituximab in the treatment of idiopathic childhood nephrotic syndrome? // Pediatr nephrol, 2007. Vol. 22. P. 893-898Stone J.H. et al. Rituximab versus cyclophosphamide for induction remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE) // Arthritis Rheum, 2009 [online]Stone J.H. et al. Rituximab versus cyclophosphamide for induction remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE) // Arthritis Rheum, 2009 [online]Vigna-Perez M., Hemandez-Castro B., Paredes-Saharopulos O. et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study // Arthritis Res Ther, 2006. Vol. 8: R83Vigna-Perez M., Hemandez-Castro B., Paredes-Saharopulos O. et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study // Arthritis Res Ther, 2006. Vol. 8: R83M. Walsh, D. Jayne. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future // Kidney Int, 2007. Vol. 72. P. 676—682M. Walsh, D. Jayne. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future // Kidney Int, 2007. Vol. 72. P. 676—682Yang T., Nast C.C., Vo A. et al. Rapid remission of steroid and mycofenolate mofetil (mmf)-resistant minimal change nephritic syndrome after rituximab therapy // NDT, 2008. Vol. 23. P. 377-380Yang T., Nast C.C., Vo A. et al. Rapid remission of steroid and mycofenolate mofetil (mmf)-resistant minimal change nephritic syndrome after rituximab therapy // NDT, 2008. Vol. 23. P. 377-380

The authors declare that there are no conflicts of interest present.